These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

357 related items for PubMed ID: 17329191

  • 1. Effect of cytomegalovirus prophylaxis with immunoglobulin or with antiviral drugs on post-transplant non-Hodgkin lymphoma: a multicentre retrospective analysis.
    Opelz G, Daniel V, Naujokat C, Fickenscher H, Döhler B.
    Lancet Oncol; 2007 Mar; 8(3):212-8. PubMed ID: 17329191
    [Abstract] [Full Text] [Related]

  • 2. Cytomegalovirus: occurrence, severity, and effect on graft survival in simultaneous pancreas-kidney transplantation.
    Ricart MJ, Malaise J, Moreno A, Crespo M, Fernández-Cruz L, Euro-SPK Study Group.
    Nephrol Dial Transplant; 2005 May; 20 Suppl 2():ii25-ii32, ii62. PubMed ID: 15814546
    [Abstract] [Full Text] [Related]

  • 3. [The significance of risk-adapted antiviral prophylaxis and modern virus diagnosis for organ survival after kidney transplantation].
    Fricke L, Steinhoff J, Hartwig-Weber I, Bein G.
    Dtsch Med Wochenschr; 1997 May 02; 122(18):565-71. PubMed ID: 9190308
    [Abstract] [Full Text] [Related]

  • 4. Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis.
    Rubin RH, Kemmerly SA, Conti D, Doran M, Murray BM, Neylan JF, Pappas C, Pitts D, Avery R, Pavlakis M, Del Busto R, DeNofrio D, Blumberg EA, Schoenfeld DA, Donohue T, Fisher SA, Fishman JA.
    Transpl Infect Dis; 2000 Sep 02; 2(3):112-7. PubMed ID: 11429021
    [Abstract] [Full Text] [Related]

  • 5. Comparing cytomegalovirus prophylaxis in renal transplantation: single center experience.
    Varga M, Remport A, Hídvégi M, Péter A, Kóbori L, Telkes G, Fazakas J, Gerlei Z, Sárváry E, Sulyok B, Járay J.
    Transpl Infect Dis; 2005 Jun 02; 7(2):63-7. PubMed ID: 16150092
    [Abstract] [Full Text] [Related]

  • 6. Cytomegalovirus infection post-pancreas-kidney transplantation--results of antiviral prophylaxis in high-risk patients.
    Fallatah SM, Marquez MA, Bazerbachi F, Schiff JR, Cattral MS, McGilvray ID, Norgate A, Selzner M, Rotstein C, Husain S.
    Clin Transplant; 2013 Jun 02; 27(4):503-9. PubMed ID: 23731387
    [Abstract] [Full Text] [Related]

  • 7. Cytomegalovirus prophylaxis in pediatric kidney transplantation: the Dutch experience.
    Jongsma H, Bouts AH, Cornelissen EA, Beersma MF, Cransberg K.
    Pediatr Transplant; 2013 Sep 02; 17(6):510-7. PubMed ID: 23890076
    [Abstract] [Full Text] [Related]

  • 8. Ganciclovir. An update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients.
    Noble S, Faulds D.
    Drugs; 1998 Jul 02; 56(1):115-46. PubMed ID: 9664203
    [Abstract] [Full Text] [Related]

  • 9. A randomized prospective controlled trial of oral acyclovir versus oral ganciclovir for cytomegalovirus prophylaxis in high-risk kidney transplant recipients.
    Flechner SM, Avery RK, Fisher R, Mastroianni BA, Papajcik DA, O'Malley KJ, Goormastic M, Goldfarb DA, Modlin CS, Novick AC.
    Transplantation; 1998 Dec 27; 66(12):1682-8. PubMed ID: 9884259
    [Abstract] [Full Text] [Related]

  • 10. Reassessing the impact of cytomegalovirus infection in kidney and kidney-pancreas transplantation.
    Becker BN, Becker YT, Leverson GE, Simmons WD, Sollinger HW, Pirsch JD.
    Am J Kidney Dis; 2002 May 27; 39(5):1088-95. PubMed ID: 11979354
    [Abstract] [Full Text] [Related]

  • 11. Historical comparison of prophylactic ganciclovir for gastrointestinal cytomegalovirus infection in kidney transplant recipients.
    Kim HC, Hwang EA, Park SB, Kim HT, Cho WH.
    Transplant Proc; 2012 Apr 27; 44(3):710-2. PubMed ID: 22483474
    [Abstract] [Full Text] [Related]

  • 12. Cytomegalovirus serostatus pairing and deceased donor kidney transplant outcomes in adult recipients with antiviral prophylaxis.
    Kuo HT, Ye X, Sampaio MS, Reddy P, Bunnapradist S.
    Transplantation; 2010 Nov 27; 90(10):1091-8. PubMed ID: 20885340
    [Abstract] [Full Text] [Related]

  • 13. Cytomegalovirus prophylaxis with ganciclovir in kidney transplant recipients receiving induction antilymphocyte antibodies.
    Said T, Nampoory MR, Johny KV, Pacsa AS, Mini Abraham P, Nair MP, Abdel-Haleem M, Samhan M, Al-Mousawi M.
    Transplant Proc; 2004 Nov 27; 36(6):1847-9. PubMed ID: 15350495
    [Abstract] [Full Text] [Related]

  • 14. A randomized prospective controlled trial of oral ganciclovir versus oral valacyclovir for prophylaxis of cytomegalovirus disease after renal transplantation.
    Reischig T, Opatrny K, Bouda M, Treska V, Jindra P, Svecova M.
    Transpl Int; 2002 Dec 27; 15(12):615-22. PubMed ID: 12478408
    [Abstract] [Full Text] [Related]

  • 15. Epidemiology of pretransplant EBV and CMV serostatus in relation to posttransplant non-Hodgkin lymphoma.
    Opelz G, Daniel V, Naujokat C, Döhler B.
    Transplantation; 2009 Oct 27; 88(8):962-7. PubMed ID: 19855238
    [Abstract] [Full Text] [Related]

  • 16. A comparative randomised study of valacyclovir vs. oral ganciclovir for cytomegalovirus prophylaxis in renal transplant recipients.
    Pavlopoulou ID, Syriopoulou VP, Chelioti H, Daikos GL, Stamatiades D, Kostakis A, Boletis JN.
    Clin Microbiol Infect; 2005 Sep 27; 11(9):736-43. PubMed ID: 16104989
    [Abstract] [Full Text] [Related]

  • 17. Randomized controlled trial of oral ganciclovir versus oral acyclovir after induction with intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in cytomegalovirus-seropositive liver transplant recipients.
    Winston DJ, Busuttil RW.
    Transplantation; 2003 Jan 27; 75(2):229-33. PubMed ID: 12548129
    [Abstract] [Full Text] [Related]

  • 18. Ganciclovir prophylaxis delays but does not prevent cytomegalovirus infection in renal transplant recipients.
    Israni A, Krok K, Cohen D, Blumberg E, Bloom RD.
    Transplant Proc; 2004 Dec 27; 36(10):3019-24. PubMed ID: 15686685
    [Abstract] [Full Text] [Related]

  • 19. Prophylactic ganciclovir is more effective in HLA-identical family member marrow transplant recipients than in more heavily immune-suppressed HLA-identical unrelated donor marrow transplant recipients. Australasian Bone Marrow Transplant Study Group.
    Atkinson K, Arthur C, Bradstock K, Dale B, Downs K, Gibson J, Golenia M, Ho J, Joshua D, Juttner C.
    Bone Marrow Transplant; 1995 Sep 27; 16(3):401-5. PubMed ID: 8535313
    [Abstract] [Full Text] [Related]

  • 20. Acyclovir prophylaxis for cytomegalovirus disease in high-risk renal transplant recipients: is it effective?
    Goral S, Ynares C, Dummer S, Helderman JH.
    Kidney Int Suppl; 1996 Dec 27; 57():S62-5. PubMed ID: 8941924
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.